Bausch & Lomb (BLCO) closed at $20.88 on November 16, 2026, down 1.0% from the previous close, on volume of 664,968 shares (30-day average 893,082).
Data as of November 16, 2026.
Business Wire (Thu, 29-Oct 7:00 AM ET)
BLCO raises full-year 2026 guidance after Q3 profit swing and broad-based segment growth
Market Chameleon (Wed, 28-Oct 7:03 AM ET)
Bausch + Lomb raises full-year 2026 guidance after Q3 profits flip positive on $1.375B revenue
Market Chameleon (Wed, 28-Oct 5:15 AM ET)
Bausch + Lomb Posts Strong Third-Quarter Performance, Raises Full-Year 2026 Guidance
Business Wire (Wed, 28-Oct 6:58 AM ET)
Business Wire (Mon, 12-Oct 6:45 AM ET)
Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting
Business Wire (Tue, 6-Oct 4:30 PM ET)
Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28
Business Wire (Mon, 5-Oct 7:30 AM ET)
Bausch + Lomb Announces European CE Mark Approval of SeeLyra Femtosecond Laser
Business Wire (Fri, 11-Sep 6:11 AM ET)
Bausch + Lomb Announces New Published Research on enVista Aspire Real World Experience
Business Wire (Wed, 2-Sep 7:00 AM ET)
Business Wire (Tue, 1-Sep 6:58 AM ET)
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes brands like Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, and surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xiidra and Miebo that treat various eye complications.
Bausch & Lomb trades on the NYSE stock market under the symbol BLCO.
As of November 16, 2026, BLCO stock price declined to $20.88 with 664,968 million shares trading.
BLCO has a beta of 0.68, meaning it tends to be less sensitive to market movements. BLCO has a correlation of 0.08 to the broad based SPY ETF.
BLCO has a market cap of $7.46 billion. This is considered a Mid Cap stock.
Last quarter Bausch & Lomb reported $1 billion in Revenue and $.34 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.12.
In the last 3 years, BLCO traded as high as $21.69 and as low as $10.45.
The top ETF exchange traded funds that BLCO belongs to (by Net Assets): MGMT, ARWG, DFAX, GVLU, DFIC.
BLCO has outperformed the market in the last year with a price return of +33.1% while the SPY ETF gained +11.2%. BLCO has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +23.0% and +4.4%, respectively, while the SPY returned -4.6% and -2.1%, respectively.
BLCO support price is $20.61 and resistance is $21.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BLCO shares will trade within this expected range on the day.